CNTN2 and colorectal carcinoma: In particular, application of the PERK inhibitor GSK or PERK siRNA significantly reduced TAX- or NOC-induced anti-CRC effects such as apoptosis and G2/M arrest, accompanied by decreased pBcl-2 (Thr 70), pCdc25C, cycB1, and pJNK protein expressions in cells.